Next Article in Journal
Specific Protocols of Controlled Ovarian Stimulation for Oocyte Cryopreservation in Breast Cancer Patients
Previous Article in Journal
Reducing Postsurgical Exudate in Breast Cancer Patients by Using San Huang Decoction to Ameliorate Inflammatory Status: A Prospective Clinical Trial
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on as a courtesy and upon agreement with Multimed Inc..

Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response

Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada
NCIC Clinical Trials Group, Queen’s University, Kingston, ON K7L 3N6, Canada
Flinders University and Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Bedford Park, SA 5042, Australia
The Queen Elizabeth and University of Adelaide, Adelaide, SA 5005, Australia
Austin Health, Melbourne, VIC 3084, Australia
Department of Medical Oncology, Monash University, Melbourne, VIC 3084, Australia
University of Western Australia, Perth, WA 6009, Australia
Royal North Shore Hospital, Northern Clinical School, University of Sydney, St. Leonards, NSW 2006, Australia
Royal Melbourne Hospital, Melbourne, VIC 3050, Australia
Oncology Service, Christchurch Hospital, Christchurch 8011, New Zealand
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5S, Canada
University of British Columbia, BC Cancer, Vancouver, BC V5Z 1L3, Canada
Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(6), 516-526;
Received: 5 September 2018 / Revised: 11 October 2018 / Accepted: 3 November 2018 / Published: 1 December 2018
Background Adrenergic receptor stimulation is involved in the development of hypertension (htn) and has been implicated in cancer progression and dissemination of metastases in various tumours, including colon cancer. Adrenergic antagonists such as beta-blockers (bbs) demonstrate inhibition of invasion and migration in colon cancer cell lines and have been associated with decreased mortality in colorectal cancer (crc). We examined the association of baseline htn and bb use with overall (os) and progression-free survival (pfs) in patients with pretreated, chemotherapy refractory, metastatic crc (mcrc). We also examined baseline htn as a predictor of cetuximab efficacy. Methods Using data from the Canadian Cancer Trials Group co.17 study [cetuximab vs. best supportive care (bsc)], we coded baseline htn and use of anti-htn medications, including bbs, for 572 patients. The chi-square test was used to assess the associations between those variables and baseline characteristics. Cox regression models were used for univariate and multivariate analyses of os and pfs by htn diagnosis and bb use. Results Baseline htn, bb use, and anti-htn medication use were not found to be prognostic for improved os. Baseline htn and bb use were not significant predictors of cetuximab benefit. Conclusions In chemorefractory mcrc, neither baseline htn nor bb use is a significant prognostic factor. Baseline htn and bb use are not predictive of cetuximab benefit. Further investigation to determine whether baseline htn or bb use have a similarly insignificant impact on prognosis in patients receiving earlier lines of treatment remains warranted.
Keywords: colorectal cancer; hypertension colorectal cancer; hypertension
MDPI and ACS Style

Sud, S.; O’Callaghan, C.; Jonker, C.; Karapetis, C.; Price, T.; Tebbutt, N.; Shapiro, J.; Van Hazel, G.; Pavlakis, N.; Gibbs, P.; Jeffrey, M.; Siu, L.; Gill, S.; Wong, R.; Jonker, D.; Tu, D.; Goodwin, R. Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response. Curr. Oncol. 2018, 25, 516-526.

AMA Style

Sud S, O’Callaghan C, Jonker C, Karapetis C, Price T, Tebbutt N, Shapiro J, Van Hazel G, Pavlakis N, Gibbs P, Jeffrey M, Siu L, Gill S, Wong R, Jonker D, Tu D, Goodwin R. Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response. Current Oncology. 2018; 25(6):516-526.

Chicago/Turabian Style

Sud, S., C. O’Callaghan, C. Jonker, C. Karapetis, T. Price, N. Tebbutt, J. Shapiro, G. Van Hazel, N. Pavlakis, P. Gibbs, M. Jeffrey, L. Siu, S. Gill, R. Wong, D. Jonker, D. Tu, and R. Goodwin 2018. "Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response" Current Oncology 25, no. 6: 516-526.

Find Other Styles

Article Access Map by Country/Region

Back to TopTop